Study guide

10.3 Pediatric Prophylaxis & Early Infant Diagnosis

Clinical Officers Council Pre-Internship Examination Kenya

Track your progress as you read

Finished sections get a check mark.

1 Chapter 1: Overview & Exam Strategy

1.1 About the COC Pre-Internship Examination 1.2 Clinical Decision-Making & Preparation Strategy

2 Chapter 2: Infectious & Communicable Diseases (Internal Medicine)

2.1 Malaria Diagnosis & Case Management 2.2 Tuberculosis & Leprosy Control 2.3 HIV/AIDS & Opportunistic Infections 2.4 Enteric & Neglected Tropical Infections

3 Chapter 3: Cardiovascular & Respiratory Medicine (Internal Medicine)

3.1 Hypertension & Cardiovascular Disorders 3.2 Respiratory Disorders & Acute Emergencies 3.3 Venous Thromboembolism & Vascular Emergencies

4 Chapter 4: Metabolic, Gastrointestinal & Neurological Medicine (Internal Medicine)

4.1 Diabetes Mellitus & Endocrine Emergencies 4.2 Gastrointestinal & Hepatorenal Disorders 4.3 Neurological Emergencies & Acute Toxicology

5 Chapter 5: Trauma Resuscitation & Emergency Surgery (General Surgery)

5.1 ATLS Primary Survey & Trauma Resuscitation 5.2 Burn Assessment & Fluid Resuscitation 5.3 Surgical Wounds, Infections & Tetanus Prophylaxis

6 Chapter 6: Acute Abdomen & Gastrointestinal Surgery (General Surgery)

6.1 Acute Appendicitis & Peritonitis 6.2 Intestinal Obstruction & Abdominal Hernias 6.3 Hepatobiliary, Pancreatic & Anorectal Surgical Conditions

7 Chapter 7: Orthopedics, Urology & Special Surgical Emergencies (General Surgery)

7.1 Fractures, Dislocations & Cast Management 7.2 Acute Compartment Syndrome & Limb Emergencies 7.3 Urological Emergencies & Pelvic Trauma 7.4 Emergency Airway, Anesthesia & Oncology Screening

8 Chapter 8: Essential Newborn Care & Neonatal Conditions (Pediatrics)

8.1 Immediate Newborn Care & Neonatal Resuscitation 8.2 Neonatal Jaundice, Sepsis & Common Disorders 8.3 Low Birth Weight & Kangaroo Mother Care

9 Chapter 9: IMCI Guidelines & Common Pediatric Conditions (Pediatrics)

9.1 IMCI Principles & General Danger Signs 9.2 Cough, Fast Breathing & Pediatric Pneumonia 9.3 Pediatric Diarrheal Diseases & Dehydration 9.4 Acute Pediatric Infections: Meningitis, Croup & Febrile Seizures

10 Chapter 10: Child Nutrition, KEPI & Preventive Pediatrics (Pediatrics)

10.1 Severe Acute Malnutrition (SAM) Management 10.2 KEPI Immunization Schedule & Vaccine Logistics 10.3 Pediatric Prophylaxis & Early Infant Diagnosis

11 Chapter 11: Antenatal Care & Medical Complications of Pregnancy (Obstetrics & Gynecology)

11.1 Focused Antenatal Care & Routine ANC Screening 11.2 Hypertensive Disorders of Pregnancy & Eclampsia 11.3 Medical Disorders & Infections in Pregnancy

12 Chapter 12: Labor, Delivery & Obstetric Emergencies (Obstetrics & Gynecology)

12.1 Normal Labor & Partograph Monitoring 12.2 Active Management of the Third Stage of Labor & PPH 12.3 Antepartum Hemorrhage & Uterine Rupture 12.4 Induction of Labor & Malpresentation Emergencies

13 Chapter 13: Puerperium, Gynecological Disorders & Family Planning (Obstetrics & Gynecology)

13.1 Puerperal Sepsis & Postnatal Complications 13.2 Pelvic Inflammatory Disease & Gynecological Conditions 13.3 Modern Contraceptive Technology & WHO MEC Criteria

14 Chapter 14: Primary Health Care & Devolved Health Systems (Community Health)

14.1 Primary Health Care Principles & Universal Health Coverage 14.2 Kenya Health Service Delivery Structure & Devolved Governance 14.3 Kenya Community Health Strategy & Level 1 Services

15 Chapter 15: Epidemiology, Disease Surveillance & Outbreak Response (Community Health)

15.1 Epidemiological Principles & Health Indicators 15.2 Integrated Disease Surveillance and Response (IDSR) 15.3 Vector Control & Neglected Tropical Diseases

16 Chapter 16: Environmental Health, Waste Management & Cold Chain (Community Health)

16.1 Water Quality & Household Water Treatment 16.2 Community Sanitation & Excreta Disposal 16.3 Healthcare Waste Management & Infection Prevention Control 16.4 Vaccine Cold Chain Management & Quality Monitoring

17 Chapter 17: Health Systems Management — Leadership, Policy & Financing

17.1 Management Functions, Leadership & Supportive Supervision 17.2 Kenya Health Policy, Planning & the Devolved Budget Cycle 17.3 Health Financing & Universal Health Coverage under the Social Health Authority 17.4 Human Resource Management, Scheme of Service & Performance Appraisal

18 Chapter 18: Health Commodities, Information & Quality Management

18.1 Health Commodity & Supply Chain Management (KEMSA) 18.2 Health Information Systems, Records & KHIS Reporting 18.3 Quality Improvement, Clinical Audit & Patient Safety

19 Chapter 19: Professional Practice, Ethics & Medico-Legal Responsibility

19.1 Scope of Practice, Registration, Licensing & Professional Discipline 19.2 Medical Ethics, Informed Consent & Patient Rights 19.3 Medico-Legal Documentation, Statutory Notification & Facility Safety Governance

10.3 Pediatric Prophylaxis & Early Infant Diagnosis

Key Takeaways Explain This Topic AI

Routine Vitamin A supplementation prevents xerophthalmia, keratomalacia, and childhood blindness while reducing all-cause under-five mortality: 100,000 IU (blue capsule) is administered at 6 to 11 months, and 200,000 IU (red capsule) is administered every 6 months from 12 to 59 months; acute measles cases require a therapeutic 3-dose protocol (Days 1, 2, and 14).

Routine preventive deworming with Albendazole (400 mg single chewable dose) or Mebendazole (500 mg) every 6 months for children aged 12 to 59 months prevents soil-transmitted helminthiasis, microcytic hypochromic anemia, and cognitive impairment.

Sickle Cell Anemia (HbSS) pediatric management requires daily prophylactic oral Penicillin V (125 mg bd for < 3 years; 250 mg bd for ≥ 3 years) up to at least age 5 to protect against fatal encapsulated Streptococcus pneumoniae bacteremia secondary to early functional autosplenectomy, co-prescribed with daily Folic Acid (1 to 5 mg).

Early Infant Diagnosis (EID) of HIV in Kenya resolves the diagnostic barrier created by transplacental maternal IgG antibodies (which persist up to 18 months) by employing HIV DNA-PCR virological testing across a standardized cascade: 1st PCR at 6 weeks (or first contact), 2nd PCR at 6 months, 3rd PCR at 12 months, and a final rapid antibody test at 18 months (or 6 weeks after cessation of breastfeeding).

All HIV-exposed infants (HEI) must receive risk-stratified infant antiretroviral prophylaxis (Zidovudine + Nevirapine for high risk; Nevirapine monotherapy for low risk) from birth, combined with daily Co-trimoxazole Preventive Therapy (CPT) initiated at 6 weeks of age to prevent Pneumocystis jirovecii pneumonia and severe bacterial infections until HIV is definitively ruled out.

Last updated: September 2026

Pediatric Prophylaxis & Early Infant Diagnosis

Preventive pediatrics forms the cornerstone of primary child health care in Kenya. Routine micronutrient supplementation, systematic chemoprophylaxis for high-risk chronic diseases, and early molecular diagnostics prevent catastrophic morbidity and premature death. The Clinical Officers Council (COC) examination routinely tests three high-yield clinical pillars: Vitamin A and deworming protocols, sickle cell anemia infection prophylaxis, and the national Early Infant Diagnosis (EID) cascade for HIV-exposed infants.

1. Vitamin A Supplementation (VAS) & Xerophthalmia Prevention

Vitamin A (retinol) is an essential fat-soluble micronutrient required for retinal rhodopsin phototransduction, ocular conjunctival goblet cell integrity, respiratory and intestinal epithelial mucosal immunity, and systemic cell-mediated immune defense. In Kenya, subclinical vitamin A deficiency is widespread in ASAL counties and informal urban settlements.

National Routine Prophylaxis Schedule

Under Kenya Ministry of Health guidelines, routine prophylactic Vitamin A is integrated into Child Welfare Clinics (CWC) and Malezi Bora child health weeks: ROUTINE VITAMIN A PROPHYLACTIC SCHEDULE:

  • 6 to 11 Months of Age:

► 100,000 IU orally (One BLUE capsule, nipple cut and squeezed into mouth) — Single dose

  • 12 to 59 Months of Age:
  • ► 200,000 IU orally (One RED capsule, nipple cut and squeezed into mouth) — Every 6 months
  • WHO Xerophthalmia Classification

Severe vitamin A deficiency produces characteristic progressive ocular manifestations:

Stage Clinical Ocular Manifestation Description

XN Night Blindness Inability to see in dim light or dusk (earliest visual sign; mother notices child stumbling at dusk)

X1A Conjunctival Xerosis Dry, dull, lusterless, non-wettable bulbar conjunctiva

X1B Bitot's Spots Raised, foamy, silvery-grey, triangular plaques of keratinized epithelium on the temporal bulbar conjunctiva

X2 Corneal Xerosis Hazy, dry, cloudy cornea; loss of normal corneal luster

X3A Corneal Ulceration / Keratomalacia (< 1/3 of cornea) Liquefactive necrosis and soft melting of the cornea involving less than one-third of the corneal surface

X3B Corneal Ulceration / Keratomalacia (≥ 1/3 of cornea) Extensive corneal melting involving more than one-third of the cornea; leads to perforation, iris prolapse, and permanent blindness

  • XS Corneal Scar Permanent white, fibrous scarring following healed ulceration
  • Therapeutic Treatment Protocol for Acute Measles, Severe SAM, or Xerophthalmia

Measles virus infection causes a profound, rapid collapse in circulating retinol concentrations, turning borderline deficiency into fulminant corneal keratomalacia. All children with acute measles , severe acute malnutrition (complicated or uncomplicated) , or clinical xerophthalmia (XN to X3B) must receive the therapeutic 3-dose regimen : THERAPEUTIC 3-DOSE VITAMIN A SCHEDULE:

  • Dose 1: Administered immediately upon diagnosis (Day 1)
  • Dose 2: Administered the following day (Day 2)
  • Dose 3: Administered 2 to 4 weeks later (Day 14 to 28)

AGE-SPECIFIC THERAPEUTIC DOSAGES (Per Dose):

  • Infants < 6 months: 50,000 IU orally
  • Infants 6 to 11 months: 100,000 IU orally (Blue capsule)
  • Children ≥ 12 months: 200,000 IU orally (Red capsule)
  • 2. Soil-Transmitted Helminthiasis & Routine Deworming

Intestinal soil-transmitted helminths (STHs)—predominantly Ascaris lumbricoides (roundworm), Trichuris trichiura (whipworm), and hookworms ( Necator americanus and Ancylostoma duodenale )—infect millions of preschool and school-age children in Kenya. Chronic infection leads to gastrointestinal blood loss, microcytic hypochromic iron-deficiency anemia, protein-losing enteropathy, stunted linear growth, and poor cognitive performance.

Kenya National Deworming Protocol

Target Population: All preschool children aged 12 to 59 months , repeated every 6 months (biannually), delivered through CWCs and National School-Based Deworming Programs (NSBDP).

First-Line Pharmacotherapy:

Oral Albendazole: 400 mg single chewable tablet (crushed between two spoons for children under 24 months; 200 mg single dose may be utilized in infants 12–23 months in select protocols, but Kenya National Guidelines recommend 400 mg for all children ≥ 12 months).

Oral Mebendazole: 500 mg single chewable tablet as an alternative.

Contraindications: Age under 12 months (routine deworming is not recommended under 1 year of age).

3. Sickle Cell Anemia (HbSS) Pediatric Chemoprophylaxis

Sickle Cell Anemia is an autosomal recessive hemoglobinopathy resulting from a point mutation (glu6val) in the beta-globin chain. In western Kenya, the Lake Victoria basin, and coastal counties, the sickle carrier trait (HbAS) reaches 15% to 20%. Children with homozygous disease (HbSS) face extreme vulnerability to severe bacterial infections and vaso-occlusive crises. SICKLE CELL ANEMIA PROPHYLAXIS PYRAMID

  • [ SURVIVAL ]
  • ▲
  • ╱ ╲
  • ╱ ╲
  • [ DAILY PENICILLIN V PROPHYLAXIS ]
  • Protects against Streptococcus pneumoniae
  • sepsis due to functional autosplenectomy
  • ╱ ╲
  • [ DAILY FOLIC ACID (1–5 mg) ]
  • Supports hyperactive erythropoiesis
  • ╱ ╲
  • [ EXPANDED VACCINATION (PCV + PPV-23) ]
  • Pneumococcal, Hib, Meningococcal, Influenza
  • ╱ ╲
  • [ HYDRATION & CRISIS PREVENTATIVE CARE ]
  • High oral fluids, prompt treatment of fever/VOC
  • Pathophysiology of Functional Autosplenectomy

The spleen normally serves as the primary reticuloendothelial filter that clears non-opsonized encapsulated bacteria and produces opsonizing antibodies. In young children with HbSS, recurrent sickling of erythrocytes in the hypoxic, acidic, and hyperosmolar splenic cords causes microvascular occlusion, tissue infarction, and fibrosis. By 6 to 12 months of age , virtually all infants with HbSS develop functional asplenia (autosplenectomy) , even if the spleen remains palpably enlarged (splenomegaly). By 5 to 6 years, recurrent infarction shrinks the spleen to a fibrotic nodule. Functional asplenia leaves children catastrophically susceptible to fulminant, fatal bacteremia caused by encapsulated bacteria—predominantly Streptococcus pneumoniae (pneumococcus) , followed by Haemophilus influenzae type b and Salmonella species (causing osteomyelitis).

Daily Penicillin V Chemoprophylaxis Protocol

Daily oral prophylaxis with Penicillin V (Phenoxymethylpenicillin) reduces pneumococcal bacteremia and mortality by over 80%: ORAL PENICILLIN V DOSING (Daily Prophylaxis):

  • Children Under 3 Years of Age:

► 125 mg orally twice daily (every 12 hours)

  • Children 3 Years of Age and Older:

► 250 mg orally twice daily (every 12 hours)

  • Duration:

► Continued continuously from diagnosis (ideally by 2–3 months of age) until AT LEAST

5 years of age (many centers in Kenya continue lifelong).

• In Penicillin-Allergic Patients:

► Oral Erythromycin: 125 mg twice daily (< 3 years) or 250 mg twice daily (≥ 3 years).

Supplementary Prophylactic Interventions in HbSS

Folic Acid: 1 to 5 mg orally once daily lifelong. Chronic intravascular and extravascular hemolysis causes hyperactive erythroid hyperplasia, rapidly depleting folate stores and precipitating acute megaloblastic aplastic crises.

Immunization: Complete KEPI schedule including 3 doses of PCV-10, plus an additional dose of 23-valent Pneumococcal Polysaccharide Vaccine (PPV-23) at 2 years of age to broaden serotype coverage.

Malaria Prophylaxis: In malaria-endemic zones of Kenya, daily or monthly chemoprophylaxis (e.g., Proguanil or seasonal chemoprevention) to avoid life-threatening malarial hemolytic crises.

Vaso-occlusive Crisis (VOC) Management: Aggressive hydration (1.5 times maintenance fluids), multimodal analgesia (paracetamol, NSAIDs, weak/strong opioids like morphine for severe pain), prompt oxygen therapy if SpO2 < 95%, and immediate empiric broad-spectrum antibiotics (IV Ceftriaxone) if fever ≥ 38.0°C occurs.

4. Early Infant Diagnosis (EID) of HIV in Kenya

Prevention of Mother-to-Child Transmission (PMTCT) and Early Infant Diagnosis (EID) algorithms are vital components of the Kenya National AIDS and STI Control Programme (NASCOP) guidelines.

The Diagnostic Dilemma: Maternal IgG Antibodies

Maternal anti-HIV Immunoglobulin G (IgG) antibodies routinely cross the syncytiotrophoblast of the placenta from the 16th week of gestation. In an infant born to an HIV-positive mother, these circulating maternal antibodies persist in infant blood for up to 18 months .

Fundamental Clinical Principle: A standard rapid antibody test (e.g., Determine, First Response) performed on an infant under 18 months of age only indicates maternal HIV exposure , NOT active infant infection. A positive antibody test in a 6-month-old infant cannot diagnose infant HIV! Definite diagnosis requires molecular virological testing that detects the viral genome.

Virological Testing: HIV DNA-PCR

Kenya uses HIV DNA-PCR performed on Dried Blood Spot (DBS) specimens obtained via infant heel prick or big-toe prick. DNA-PCR detects proviral HIV-1 DNA integrated inside infant host peripheral blood mononuclear cells. KENYA NATIONAL EID VIROLOGICAL TESTING CASCADE:

  • [BIRTH PCR (Day 0–14)]
  • Targeted testing for HIGH-RISK HIV-exposed infants (mother unsuppressed VL,

on ART < 4 weeks, or adolescent mother).

  • │
  • ▼
  • [FIRST ROUTINE PCR: 6 WEEKS (Or First Contact)]
  • Mandatory for ALL HIV-Exposed Infants (HEI) attending the 6-week CWC visit.
  • │
  • ▼
  • [SECOND ROUTINE PCR: 6 MONTHS]
  • Routine virological monitoring for all infants who tested negative at 6 weeks.
  • │
  • ▼
  • [THIRD ROUTINE PCR: 12 MONTHS]
  • Routine virological check for all breastfeeding/previously exposed children.
  • │
  • ▼
  • [ADDITIONAL PCR TESTS (Event-Driven)]
  • At any point if the child becomes symptomatic with clinical features of HIV.
  • Exactly 6 WEEKS AFTER COMPLETE CESSATION OF BREASTFEEDING (if under 18 months).
  • │
  • ▼
  • [FINAL RAPID ANTIBODY TEST: 18 MONTHS]
  • Performed at 18 months of age (or 6 weeks after cessation of breastfeeding,
  • whichever is LATER) to confirm complete clearance of maternal antibodies

and definitive HIV-free status.

Action on Positive HIV DNA-PCR Test

If an infant's DNA-PCR returns POSITIVE at any point:

IMMEDIATE ACTION: Contact caregiver and initiate full pediatric Antiretroviral Therapy (pART) IMMEDIATELY . Do not delay ART while awaiting confirmatory testing.

Confirmatory Testing: Draw a second blood sample immediately for a confirmatory PCR test to rule out laboratory cross-contamination or sample mix-up, but start ART on Day 1.

  • 5. Infant ARV Prophylaxis & Co-Trimoxazole Preventive Therapy (CPT)
  • Risk Stratification of HIV-Exposed Infants (HEI)

Upon delivery, every HIV-exposed infant is categorized into a risk tier based on maternal adherence and viral suppression:

Low-Risk Infant: Mother has been on combination ART for at least 4 weeks prior to delivery AND has a documented suppressed viral load ( < 1,000 copies/mL ) within the last 6 months.

High-Risk Infant: Mother on ART for < 4 weeks; mother with unsuppressed viral load (≥ 1,000 copies/mL) at delivery; mother diagnosed with HIV during labor, delivery, or postpartum; or mother with interrupted treatment.

Infant ARV Prophylaxis Regimens

  • Infant Risk Category Prophylactic ARV Regimen Duration
  • Low Risk Oral Nevirapine (NVP) once daily 6 weeks

High Risk Dual Prophylaxis: Oral Zidovudine (AZT) twice daily PLUS oral Nevirapine (NVP) once daily AZT for 12 weeks ;; NVP continued daily until 6 weeks after complete cessation of breastfeeding

Co-Trimoxazole Preventive Therapy (CPT)

Indication: Co-trimoxazole protects against fatal opportunistic infections, predominantly Pneumocystis jirovecii pneumonia (PJP/PCP) , as well as cerebral toxoplasmosis, malaria, severe bacterial diarrhea, and pneumonia.

Initiation Timing: Administered to ALL HIV-exposed infants starting at 6 WEEKS of age (coinciding with the first routine immunization visit and first DNA-PCR).

Pediatric Formulation & Dosage:

Oral suspension (240 mg/5 mL: 40 mg Trimethoprim / 200 mg Sulfamethoxazole): 2.5 mL daily for infants < 5 kg; 5.0 mL daily for infants 5 to 14.9 kg.

Infant tablet (120 mg: 20 mg TMP / 100 mg SMX): 1 tablet daily for infants < 5 kg; 2 tablets daily for 5 to 14.9 kg.

Discontinuation Criteria: CPT can only be safely discontinued when:

The child is confirmed HIV-uninfected on final antibody testing after complete cessation of all breastfeeding, AND

The child is clinically stable and healthy.